| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 800017000 | Swine | 26 |
| 20090049562 | PORCINE CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE GENE - The present invention provides porcine CMP-N-Acetylneuraminic-Acid Hydroxylase (CMP-Neu5Ac hydroxylase) protein, cDNA, and genomic DNA regulatory sequences. Furthermore, the present invention includes porcine animals, tissues, and organs, as well as cells and cell lines derived from such animals, tissues, and organs, which lack expression of functional CMP-Neu5Ac hydroxylase. Such animals, tissues, organs, and cells can be used in research and in medical therapy, including in xenotransplantation, and in industrial livestock farming operations. | 02-19-2009 |
| 20090049563 | USING CYTOSINE DEAMINASES TO DIMINISH RETROELEMENT TRANSFER FROM PIGS TO HUMANS - Transgenic pigs that express one or more non-porcine cytosine deaminases are described as well as methods of making and using such pigs. | 02-19-2009 |
| 20090119787 | CELL NUCLEAR TRANSFER - The present invention discloses methods for cell nuclear transfer that comprise for example modification of zona pellucida of an oocyte, and/or sectioning of oocytes into several parts. The present invention also discloses methods for producing a genetically modified non-human mammal. Genetically modified non-human mammals obtainable by the disclosed methods are also within the scope of the present invention. Disclosed are also methods for cryopreservation of cells. | 05-07-2009 |
| 20090158450 | METHOD FOR THE TRANSFER OF EPISOMAL VECTORS INTO ANIMAL CELLS - The present invention refers to a method for the transfer of DNA sequences or exogenous genes into animal sperm cells by means of the use of episomal vectors. The invention also relates to the use of “Sperm Mediated Gene Transfer” (SMGT) technology for the creation of genetically modified individuals. | 06-18-2009 |
| 20090271882 | Transgenic Pig with Diabetes and Method for Producing the Same - A transgenic animal having diabetes, which is more suitable as a model of human than rodents, and its preparation method are disclosed. The method for preparing the transgenic pig comprises introducing a nucleic acid into a fertilized egg, clonal egg or embryo, the nucleic acid comprising a foreign gene which contains a region encoding dimerization domain of hepatocyte nuclear factor-1α, but does not encode a normal hepatocyte nuclear factor-1α, and a promoter located upstream of the foreign gene, which promoter is capable of expressing the foreign gene in a pig cell; and developing an individual from the fertilized egg, clonal egg or embryo. | 10-29-2009 |
| 20100115640 | Methods for Conditional and Inducible Transgene Espression to Direct the Development of Embryonic, Embryonic Stem, Precursor and Induced Pluripotent Stem Cells - Methods are disclosed in which the expression of a specific gene, or combinations of genes, is controlled spatially and temporally to develop intra- and interspecies chimeras. A transgenic EC/ES/P/iPS cell line is created which conditionally expresses a suicide or compromiser gene configured to compromise all cell lineages except that corresponding to a target tissue/organ. The EC/ES/P/iPS cell line is injected into donor embryos having a specific target gene deficiency or embryos genetically engineered to be complementary compromised in lineages corresponding to the target tissue/organ cell lineages of the EC/ES/P/iPS line. One or more stimuli is provided to the embryo to activate compromiser genes for ablation of non-target tissues/organs of the EC/ES/P/iPS line and target tissues/organs of the host embryo, resulting in a chimeric animal having target tissues/organs derived from the genotype of the transgenic cell line and all remaining tissues/organs derived from the donor embryo. | 05-06-2010 |
| 20100115641 | GFP-TRANSFECTED CLON PIG, GT KNOCK-OUT CLON PIG AND METHODS FOR PRODUCTIONS THEREOF - Disclosed are a cloned pig expressing green fluorescent protein (GFP) and a cloned pig having a 1,3-galactosyltransferase (GT) gene knocked out. Also, the present invention discloses methods of producing such cloned pigs, comprising the steps of establishing a somatic cell line; preparing a GFP-transfected or GT gene knock-out nuclear donor cell; producing a transgenic nuclear transfer embryo using the nuclear donor cell and a recipient oocyte; and transplanting the transgenic nuclear transfer embryo into a surrogate mother pig. The cloned pig expressing GFP of the present invention is useful for large-scale production of an animal disease model, and the GT gene knock-out cloned pig can be used as a organ donor allowing xenotransplantation in humans without hyperacute immune rejection. | 05-06-2010 |
| 20100251395 | USING CYTOSINE DEAMINASES TO DIMINISH RETROELEMENT TRANSFER FROM PIGS TO HUMANS - Transgenic pigs that express one or more non-porcine cytosine deaminases are described as well as methods of making and using such pigs. | 09-30-2010 |
| 20100299770 | TARGETED CELL DEATH - The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential. | 11-25-2010 |
| 20110016546 | PORCINE GENOME EDITING WITH ZINC FINGER NUCLEASES - The present invention provides a genetically modified porcine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the porcine genome. | 01-20-2011 |
| 20110083201 | COMPOSITIONS FOR AND METHODS OF GRAZYME B INHIBITION - The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B inhibitory serpin, methods for treating a patient in need of immunosuppression by administration of a granzyme B inhibitory serpin, and methods of transplanting cells (e.g., islet cells) expressing a granzyme B inhibitory serpin. | 04-07-2011 |
| 20120017288 | Anticoagulant Fusion Protein Anchored to Cell Membrane - The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation). | 01-19-2012 |
| 20120255047 | Porcine Animals Lacking Any Expression of Functional Alpha 1,3 Galactosyltransferase - The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes. | 10-04-2012 |
| 20120278910 | Transgenic Pig in which HO-1 and TNFR1-Fc are Simultaneously Expressed, and Method for Producing Same - The present invention relates to a method for producing a transgenic pig in which immune rejection response is inhibited, and in which human HO-1 genes and TNFR1-Fe fusion genes are simultaneously expressed. The present invention also relates to a transgenic pig for organ transplantation, which is produced by the method, and in which immune rejection response is inhibited. The present invention also relates to a somatic-cell-donating cell strain for producing the transgenic pig, and to a method for producing organs, from the transgenic pig, in which the immune rejection response is inhibited. | 11-01-2012 |
| 20120331576 | Pathogen Restriction Factors - The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein | 12-27-2012 |
| 20130024961 | Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs - The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided. | 01-24-2013 |
| 20130111614 | METHODS AND MATERIALS FOR REDUCING CARDIAC XENOGRAFT REJECTION | 05-02-2013 |
| 20130276157 | CYB5 AND CYP17 MUTATIONS FOR ALTERATION OF 16-ANDROSTENE STEROID SYNTHESIS AND REDUCED BOAR TAINT IN PIGS - Novel mutations in cytochrome P450C17 (CYP17) and cytochrome b5 (CYB5) affecting 16-androstene steroid synthesis are disclosed. The novel mutations result in alterations in production of critical intermediaries in the synthesis of 16-androstene steroids. Altering the activity of these enzymes may be useful in enhancing reducing androstenone synthesis and reducing boar taint. The identification of these novel mutations also allows for the development of transgenic pigs bearing mutations in these enzymes or for genetic screening to identify pigs on the basis of their CYP17 and/or CYB5 genotype. Pigs having these mutations may be selected and bred to produce pigs that have a lower incidence of boar taint. | 10-17-2013 |
| 20140096275 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS - The disclosure relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD 163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided. | 04-03-2014 |
| 20140115728 | DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES - The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional αGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided. | 04-24-2014 |
| 20140201858 | METHODS FOR SITE-SPECIFIC GENETIC MODIFICATION IN STEM CELLS USING XANTHOMONAS TAL NUCLEASES (XTN) FOR THE CREATION OF MODEL ORGANISMS - The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a | 07-17-2014 |
| 20140351965 | SWINE GENETICALLY MODIFIED WITH SPECIFICITY FOR LDL-R KNOCKOUT - Compositions and methods for swine LDL-R gene knockouts. | 11-27-2014 |
| 20150106962 | MINIATURE SWINE TRANSGENIC FOR ONE OR MORE COAGULATION FACTORS - Transgenic swine that express human coagulation factors, e.g., human coagulation factor VII, and/or one or more of human coagulation factors II, X and XII, and do not express the corresponding porcine coagulation factor or factors, as well as cells, tissues and organs derived therefrom, and their use in transplantation procedures. | 04-16-2015 |
| 20150106963 | CYB5 AND CYP17 MUTATIONS FOR ALTERATION OF 16-ANDROSTENE STEROID SYNTHESIS AND REDUCED BOAR TAINT IN PIGS - Novel mutations in cytochrome P450C17 (CYP17) and cytochrome b5 (CYB5) affecting 16-androstene steroid synthesis are disclosed. The novel mutations result in alterations in production of critical intermediaries in the synthesis of 16-androstene steroids. Altering the activity of these enzymes may be useful in enhancing reducing androstenone synthesis and reducing boar taint. The identification of these novel mutations also allows for the development of transgenic pigs bearing mutations in these enzymes or for genetic screening to identify pigs on the basis of their CYP17 and/or CYB5 genotype. Pigs having these mutations may be selected and bred to produce pigs that have a lower incidence of boar taint. | 04-16-2015 |
| 20150135344 | METHODS OF MODULATING THROMBOCYTOPENIA AND MODIFIED TRANSGENIC PIGS - The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided. | 05-14-2015 |
| 20160165860 | Domain 5 of CD163 for Use in Antiviral Compositions Against PRRS, and Transgenic Animals | 06-16-2016 |
